

### Company Overview

Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by rescuing and repositioning drug candidates that others have tried, but failed, to develop and developing new drugs of its own using advanced genomics and artificial intelligence ("AI"). Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures aimed at helping identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to assist with its objective of delivering cancer therapies to patients as quickly and efficiently as possible.

Lantern's current therapy product pipeline consists of three drug candidates, two in clinical stages and one in preclinical, all focusing on cancers that have distinct and unmet clinical needs with a clearly defined patient population. Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby creating the potential to achieve better outcomes.

### Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma

Jan 4 2021, 7:00 AM EST

### Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

Dec 17 2020, 7:00 AM EST

### Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Dec 15 2020, 7:00 AM EST

### Stock Overview

Symbol	LTRN
Exchange	Nasdaq
Market Cap	90.22m
Last Price	\$14.51
52-Week Range	\$10.40 - \$24.85

01/14/2021 04:00 PM EST

### Management Team

#### Panna Sharma

Chief Executive Officer, President and Director

#### David R. Margrave

Chief Financial Officer and Secretary

#### Kishor G. Bhatia, Ph.D.

Chief Scientific Officer

---

### Lantern Pharma Inc.

1920 McKinney Avenue  
7th Floor  
Dallas, TX 75201

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly

reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.